Presenting at the Annual Immuno-Oncology Summit | 17-Apr-2024 | 07:00 | RNS |
Block Listing Six Monthly Return | 16-Apr-2024 | 07:00 | RNS |
Employee exercise of share options | 03-Apr-2024 | 07:00 | RNS |
Scancell to Present at 2024 AACR Annual Meeting | 02-Apr-2024 | 07:00 | RNS |
Scancell Appoints WG as Joint Broker | 28-Mar-2024 | 13:21 | RNS |
First iSCIB1+ patient dosed | 26-Mar-2024 | 12:22 | RNS |
Appointment of Sath Nirmalananthan to the Board | 14-Mar-2024 | 11:17 | RNS |
Presenting at Next-Gen Immuno-Oncology Conference | 04-Mar-2024 | 07:00 | RNS |
Change of Auditor | 20-Feb-2024 | 07:00 | RNS |
Directorate Change | 05-Feb-2024 | 07:00 | RNS |
Interim Results | 30-Jan-2024 | 07:00 | RNS |
Notice of Interim Results and Presentation | 26-Jan-2024 | 07:00 | RNS |
Update on SCOPE trial | 17-Jan-2024 | 13:46 | RNS |
Holding(s) in Company | 28-Dec-2023 | 17:36 | RNS |
Holding(s) in Company | 27-Dec-2023 | 11:38 | RNS |
Currency | UK Pounds |
Share Price | 9.60p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 17.00 |
52 Week Low | 8.15 |
Volume | 111,474 |
Shares Issued | 927.98m |
Market Cap | £89.09m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
15:10 | 10,833 @ 9.52p |
14:08 | 3,000 @ 9.52p |
11:50 | 1,000 @ 9.43p |
11:41 | 105 @ 9.52p |
11:25 | 5,253 @ 9.52p |
CEO | Lindy Durrant |
CFO | Sath Nirmalananthan |
You are here: research